2027 RISE UP Agenda

Thursday, April 15, 2027

2:00 PM - 2:05 PM

Conference Welcome

Shared Decision Making at the Crossroads of Breast Cancer and Women’s Health: Why studies matter

Plenary

The Coming Revolution in Medicine: Germline testing as a baseline for directing interventions to maintain health and tailor screening and prevention

Session 1

Implementing Next-Generation Risk-Based Screening Around the Globe and Opportunities for Managing High-Risk Populations

Session 2

New Modifiable Risk Markers: How will they enable trials and shared decision making in practice?

I2I 2026 Winner Talk

Certitude™: the first blood-based test for early breast cancer screening

Friday, April 16, 2027

I2I 2026 Winner Talk

Enabling Clinical Translation of the ENDORA program: Preclinical Safety, Tolerability, and Mammographic Density Assessment of a Dual-Purpose (Z)-Endoxifen/Progestin Oral Therapy

Session 3

New Opportunities for Contraception: What is the burden of proof?

Session 4

Family Planning Through the Lens of Breast Cancer: How can we incorporate risk reduction as the age of first pregnancy shifts to 30 and beyond?

SPARK 2026 Winner Talk

Metabolic Impact of Abrupt Involution on Breast Cancer and Omega-3 Dietary Interventions

Session 5

Radically Rethinking Safe and Affordable Drug Development for Menopause Transition Health

SPARK 2026 Winner Talk

Leveraging the advent of oral GnRH antagonists and removal of the black-box warning against estrogen use: The BRACERR study (BRcA1 Elagolix Risk Reduction)

Session 6

Clinical Crossroads: Why are we struggling to advance solutions to reduce morbidity for uterine/OBGYN conditions, ovarian suppression, and breast cancer prevention?

Session 7

A Framework for Shared Decision Making for Hormone Replacement for Cancer Patients and Women at High Risk: What do we know, and what do we still need to generate new evidence?

Session 8

Beyond Family Planning: Reproductive autonomy in a changing landscape

Saturday, April 17, 2027

Session 9

Innovative Strategies for Community-Engaged Research to Accelerate Progress in Women’s Health

Session 10

DCIS/High-Risk as an Opportunity for Prevention: Enabling shared decision making in trials and practice

Session 11

Generating and Testing Multimodal De-Escalation Strategies: What is the best approach?

Session 12

Optimizing Early Endpoints to Accelerate the Learning Cycle: Imaging and ctDNA

Session 13

Where Are We Least Successful in Treatment? Strategies for Immune-Negative Subtypes

2026 SPARK Winner Talk

Reprogramming Immune Dysfunction in Premalignant Breast Tissue to Enable Precision Prevention (PCSK9)

Session 14

Metabolic Prevention Strategies for High-Risk Cancers

Who should be on a GLP-1 at the time of breast cancer diagnosis, what are the tradeoffs, and should we allow them on trials? Should we prescribe high-fiber diets for immune-driven tumors?